Supernus End Period Cash Flow vs Change In Cash Analysis

SUPN Stock  USD 35.57  0.02  0.06%   
Supernus Pharmaceuticals financial indicator trend analysis is much more than just breaking down Supernus Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Supernus Pharmaceuticals is a good investment. Please check the relationship between Supernus Pharmaceuticals End Period Cash Flow and its Change In Cash accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

End Period Cash Flow vs Change In Cash

End Period Cash Flow vs Change In Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Supernus Pharmaceuticals End Period Cash Flow account and Change In Cash. At this time, the significance of the direction appears to have weak relationship.
The correlation between Supernus Pharmaceuticals' End Period Cash Flow and Change In Cash is 0.3. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Change In Cash in the same time period over historical financial statements of Supernus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Supernus Pharmaceuticals' End Period Cash Flow and Change In Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Supernus Pharmaceuticals are associated (or correlated) with its Change In Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Cash has no effect on the direction of End Period Cash Flow i.e., Supernus Pharmaceuticals' End Period Cash Flow and Change In Cash go up and down completely randomly.

Correlation Coefficient

0.3
Relationship DirectionPositive 
Relationship StrengthVery Weak

End Period Cash Flow

Change In Cash

Most indicators from Supernus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Supernus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.At this time, Supernus Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 24th of December 2024, Tax Provision is likely to grow to about 17.1 M, while Sales General And Administrative To Revenue is likely to drop 0.37.
 2021 2022 2023 2024 (projected)
Interest Expense23.4M7.1M2.4M2.3M
Depreciation And Amortization32.6M85.6M84.9M89.1M

Supernus Pharmaceuticals fundamental ratios Correlations

0.680.50.50.610.630.420.420.47-0.270.460.63-0.140.640.70.930.60.410.580.470.910.610.530.690.450.94
0.680.850.80.850.890.640.80.85-0.070.690.96-0.470.950.920.650.850.750.840.80.880.970.860.990.80.65
0.50.850.50.70.590.340.930.560.160.770.75-0.530.910.660.420.740.860.530.690.660.940.670.870.490.45
0.50.80.50.730.910.650.50.91-0.30.440.88-0.360.710.910.490.680.440.950.710.690.740.720.780.940.47
0.610.850.70.730.770.410.790.780.030.310.8-0.420.820.820.540.940.360.830.530.70.810.650.870.780.54
0.630.890.590.910.770.840.570.97-0.260.530.97-0.270.820.980.630.770.510.940.670.810.810.90.870.890.61
0.420.640.340.650.410.840.270.82-0.280.480.760.080.580.750.460.470.410.680.480.610.540.890.610.640.43
0.420.80.930.50.790.570.270.580.170.510.71-0.610.850.620.30.830.680.580.560.550.880.610.820.530.32
0.470.850.560.910.780.970.820.58-0.240.440.94-0.280.780.940.460.750.460.940.640.690.780.880.830.920.43
-0.27-0.070.16-0.30.03-0.26-0.280.17-0.24-0.02-0.15-0.28-0.03-0.27-0.120.030.03-0.21-0.01-0.150.01-0.08-0.08-0.15-0.09
0.460.690.770.440.310.530.480.510.44-0.020.65-0.270.750.580.470.360.920.350.740.640.760.640.70.350.51
0.630.960.750.880.80.970.760.710.94-0.150.65-0.430.890.970.610.790.680.920.80.830.920.920.930.890.6
-0.14-0.47-0.53-0.36-0.42-0.270.08-0.61-0.28-0.28-0.27-0.43-0.38-0.31-0.12-0.34-0.51-0.4-0.65-0.29-0.55-0.29-0.42-0.45-0.14
0.640.950.910.710.820.820.580.850.78-0.030.750.89-0.380.870.610.880.760.720.680.830.960.80.980.660.62
0.70.920.660.910.820.980.750.620.94-0.270.580.97-0.310.870.660.790.560.930.710.850.860.850.920.880.66
0.930.650.420.490.540.630.460.30.46-0.120.470.61-0.120.610.660.570.380.540.470.930.550.530.660.430.99
0.60.850.740.680.940.770.470.830.750.030.360.79-0.340.880.790.570.410.760.430.730.810.660.890.670.56
0.410.750.860.440.360.510.410.680.460.030.920.68-0.510.760.560.380.410.40.810.620.830.660.730.40.41
0.580.840.530.950.830.940.680.580.94-0.210.350.92-0.40.720.930.540.760.40.690.730.770.80.810.970.53
0.470.80.690.710.530.670.480.560.64-0.010.740.8-0.650.680.710.470.430.810.690.680.830.730.740.750.48
0.910.880.660.690.70.810.610.550.69-0.150.640.83-0.290.830.850.930.730.620.730.680.80.750.870.640.92
0.610.970.940.740.810.810.540.880.780.010.760.92-0.550.960.860.550.810.830.770.830.80.820.970.740.57
0.530.860.670.720.650.90.890.610.88-0.080.640.92-0.290.80.850.530.660.660.80.730.750.820.820.770.53
0.690.990.870.780.870.870.610.820.83-0.080.70.93-0.420.980.920.660.890.730.810.740.870.970.820.750.66
0.450.80.490.940.780.890.640.530.92-0.150.350.89-0.450.660.880.430.670.40.970.750.640.740.770.750.42
0.940.650.450.470.540.610.430.320.43-0.090.510.6-0.140.620.660.990.560.410.530.480.920.570.530.660.42
Click cells to compare fundamentals

Supernus Pharmaceuticals Account Relationship Matchups

Supernus Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding53.8M53.7M54.4M61.7M55.5M42.6M
Total Assets1.2B1.5B1.7B1.7B1.3B676.1M
Short Long Term Debt Total375.6M390.3M420.6M438.0M41.5M39.5M
Other Current Liab3.2M226.1M292.3M268.7M279.9M293.9M
Total Current Liabilities160.6M245.1M315.4M688.0M290.2M154.7M
Total Stockholder Equity595.4M744.9M815.9M886.2M921.5M967.6M
Property Plant And Equipment Net38.3M37.8M17.0M15.2M42.5M44.7M
Net Debt194.2M101.7M217.1M344.8M(33.5M)(31.9M)
Retained Earnings199.5M326.5M379.9M481.2M482.6M506.7M
Accounts Payable10.1M6.1M9.3M10.5M2.0M1.9M
Cash181.4M288.6M203.4M93.1M75.1M116.1M
Non Current Assets Total687.6M873.7M1.1B968.4M784.6M823.8M
Non Currrent Assets Other615K8.0M(36.1M)(10.0M)8.5M8.9M
Cash And Short Term Investments347.1M422.5M339.7M461.3M254.9M201.2M
Net Receivables87.3M140.9M148.9M165.5M144.2M151.4M
Common Stock Total Equity51K52K53K54K62.1K40.8K
Short Term Investments165.7M133.9M136.2M368.2M179.8M98.1M
Liabilities And Stockholders Equity1.2B1.5B1.7B1.7B1.3B676.1M
Non Current Liabilities Total404.3M514.1M557.9M128.3M66.0M62.7M
Inventory26.6M48.3M86.0M91.5M77.4M81.3M
Other Current Assets11.6M37.4M54.0M15.8M16.7M11.7M
Other Stockholder Equity388.4M409.3M434.3M408.1M439.5M279.8M
Total Liab564.9M759.2M873.3M816.3M356.2M324.8M
Property Plant And Equipment Gross38.3M37.8M33.4M28.2M28.9M30.4M
Total Current Assets472.6M630.4M601.6M734.2M493.1M305.3M
Accumulated Other Comprehensive Income7.4M9.0M1.5M(3.2M)(593K)(563.4K)
Intangible Assets24.8M442.3M784.7M702.5M599.9M629.9M
Common Stock51K52K53K54K55K42.0K
Other Liab28.7M123.8M137.4M92.3M106.2M111.5M
Current Deferred Revenue144.4M122.4M126.2M49.8M1.00.95
Other Assets32.7M259.7M13.9M10.9M12.5M11.9M
Long Term Debt329.5M345.2M361.8M379.3M436.1M457.9M
Short Term Debt2.8M12.8M13.7M408.8M8.3M7.9M
Property Plant Equipment17.1M37.8M52.3M44.1M50.7M53.2M
Net Tangible Assets570.6M302.6M(86.4M)66.7M76.7M72.9M
Good Will24.8M77.9M117.5M117.0M134.6M141.3M
Retained Earnings Total Equity199.5M326.5M379.9M481.2M553.4M581.1M
Capital Surpluse388.4M409.3M434.3M408.1M469.3M352.1M

Pair Trading with Supernus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Supernus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Supernus Stock

  0.86VINC Vincerx PharmaPairCorr
  0.83ME 23Andme HoldingPairCorr
  0.75VALN Valneva SE ADRPairCorr
  0.74VIRX Viracta TherapeuticsPairCorr
  0.69DOMH Dominari HoldingsPairCorr
The ability to find closely correlated positions to Supernus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Supernus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Supernus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Supernus Pharmaceuticals to buy it.
The correlation of Supernus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Supernus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Supernus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Supernus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.99)
Earnings Share
1.07
Revenue Per Share
11.877
Quarterly Revenue Growth
0.142
Return On Assets
0.0289
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.